are undertaken to avoid or reduce these complications of Introduction long-term therapy [5, 6] . Fractionation of the daily levodopa dose and combination of lower doses of levodopa with a Treatment with 3,4-dihydroxyphenyl-l-alanine (levodopa) constitutes the cornerstone in the symptomatic therapy of dopamine receptor agonist (e.g. bromocriptine, apomorphine) are commonly employed [6, 7] . A strategy which is still Parkinson's disease [1] . However, oral administration of levodopa as such results in a rapid decarboxylation to under experimental clinical development is addition of an inhibitor of catechol-O-methyltransferase (COMT) to the dopamine, a reaction catalysed by aromatic l-amino acid decarboxylase [2] . Peripherally circulating dopamine is combination of levodopa and a decarboxylase inhibitor [8] .
COMT inhibitors such as tolcapone and entacapone have responsible for a spectrum of side effects of levodopa therapy, viz. nausea, vomiting and orthostatic hypotension. been shown to be well tolerated and to enhance the bioavailability of levodopa by reducing its biotransformation Combination therapy of levodopa with an inhibitor of extracerebral decarboxylase such as benserazide (MadoparA) to 3-O-methyldopa (3-OMD) [9, 10] . The currently available levodopa/decarboxylase inhibitor or carbidopa (SinemetA) leads to a marked reduction in both the required levodopa dose and the incidence of formulations contain a fixed combination of both compounds, i.e. levodopa: benserazide 451 and levodopa: unwanted effects attributable to the peripheral formation of dopamine [3] . Long-term therapy with levodopa and a carbidopa 1051 and 451. The above mentioned strategies to combat side effects of chronic levodopa therapy all imply a decarboxylase inhibitor, however, can lead to fluctuations in clinical response such as dyskinesias, end-of-dose wearing reduction of the levodopa and, therefore, also of the decarboxylase inhibitor dose. The effects of low doses of off and the 'on-off ' phenomenon [4] . Several approaches benserazide and carbidopa have not yet been investigated in * This paper is dedicated to the memory of the late Professor Mosè detail. The influence of relatively high doses of carbidopa Da Prada (1934 -1995 who for more than 30 years was engaged on the pharmacokinetics of levodopa has been described in research on levodopa and benserazide.
previously [11] . The relationship between plasma benserazide or carbidopa concentrations, gut and systemic decarboxylase inhibition and levodopa pharmacokinetics have not been Assessments determined [12] . Insufficient inhibition of decarboxylase would lead to an increase in dopamine-related side effects.
Tolerability Adverse events were assessed by spontaneous reports, observations, and questioning at regular intervals. The objectives of this study were to assess the effects of different dosage regimens of benserazide on levodopa and
The intensity of the adverse events was rated on a threepoint scale (mild, moderate, severe). Blood pressure and 3-OMD plasma levels, as existing endogenously and after administration of a fixed levodopa dose. Plasma levels of heart rate and the ECG were recorded and brief neurological examinations performed at frequent intervals on the days of 3-OMD are an indirect marker for the degree of dopamine formation because in the presence of a decarboxylase levodopa/3-OMD/DOPAC determinations. Several routine laboratory safety tests on blood and urine were conducted inhibitor the metabolism of levodopa is shifted towards 3-OMD [13, 14] . Plasma levels of 3,4-dihydroxyphenylacetic during the study. acid (DOPAC), which is formed from dopamine by monoamine oxidase (MAO) B activity, were also measured.
Pharmacokinetics Blood samples of 5 ml were collected into tubes containing heparin as anticoagulant via a polyethylene catheter inserted into a forearm vein at 1, 2, 2. Plasma samples were stored at −70°C pending analysis. subjects gave their written informed consent before any Plasma concentrations of levodopa and 3-OMD were screening procedures were performed. The study was determined by high-pressure liquid chromatography (h.p.l.c.) conducted in full conformity with the principles of the with column switching and electrochemical detection Declaration of Helsinki and its amendments. Volunteers according to a method described previously [16] . DOPAC were considered to be healthy on the basis of medical concentrations were measured by a method involving history, results of physical and neurologic examination, and adsorption to aluminium oxide at pH 8.6, desorption with electrocardiographic and routine clinical laboratory determiperchloric acid and quantification by reversed h.p.l.c. with nations. No concomitant medication was allowed during electrochemical detection. Endogenous levels of all comthe study. For a major part the study was conducted on an pounds could be determined and the lower limits of ambulatory basis. quantification were 5 mg l −1 for levodopa and DOPAC and 10 mg l −1 for 3-OMD. The intra-and inter-assay coefficients of variation were lower than 3% and 4%, respectively, over Study design the concentration range 5-3000 mg l −1 for levodopa and DOPAC and 10-3000 mg l −1 for 3-OMD, respectively. This was an open-label, parallel-group study. The second group of eight subjects started treatment 1 week after the subjects in the first group. On study days 3-16, 17-30 and Evaluation 31-44 subjects in group I received treatment with benserazide 5 mg three times daily, 25 mg three times daily and Tolerability The adverse events and clinical laboratory data were evaluated descriptively. Clinical laboratory values were 100 mg three times daily, respectively. On the same study days, subjects in group II received benserazide 12.5 mg three compared with the normal ranges supplied by the analysing laboratory. Individual vital signs were screened for times daily, 50 mg three times daily and 200 mg three times daily, respectively. Doses of up to 1300 mg daily of values outside the predetermined normal ranges: systolic blood pressure, 80-160 mmHg; diastolic blood pressure, benserazide have been given to Parkinsonian patients in previous clinical trials [15] . Benserazide in this study was 50-95 mmHg; pulse rate, 40-120 beats min
. Particular attention was devoted to signs of increased dopaminergic provided in capsules and administered at 08.00, 15.00 and 23.00 h. Endogenous plasma levels of levodopa, 3-OMD activity, viz. dizziness when standing up, nausea and vomiting. Mean vital signs data were screened for trends. and DOPAC were determined in all subjects on days −1, 14, 28 and 42. Levels of levodopa, 3-OMD and DOPAC were also measured following administration of a single oral Pharmacokinetics Pharmacokinetic parameters were determined for levodopa, 3-OMD and DOPAC. The endogenous dose of 250 mg levodopa (provided as a tablet LarodopaA) on days 1, 15, 29 and 43 at approximately 10.00 h. This (predose) concentrations were subtracted for calculation of the pharmacokinetic parameters of the exogenous dose [10] . dose of levodopa was chosen because it is sufficiently high to provide plasma concentrations which can be used for
The maximum plasma concentration (C max ) and the time to its occurrence (t max ) were read directly from the plasma pharmacokinetic evaluation, even in the absence of benserazide. Levels of levodopa, 3-OMD and DOPAC were concentration-time data. The terminal elimination rate constant (l z ) was obtained by log-linear regression analysis determined after an overnight fast which continued for 3.5 h after levodopa intake.
of the terminal portion of the curve (exogenous levodopa).
The elimination half-life (t 1/2,z ) was calculated using ln(2)/l z . cold during treatment with benserazide 25 mg three times daily. Another subject reported severe diarrhoea for 30 min For levodopa and DOPAC, only concentrations measured up to 8-10 h after drug intake were used for calculation of while on benserazide 100 mg three times daily. Finally, a subject treated with benserazide 200 mg three times daily l z , since concentrations measured thereafter were in the endogenous range. For 3-OMD, concentrations measured had a severe headache for 1 day. Influenza and headache events were in several cases treated with paracetamol. There from 8 to 33 h after drug intake were used for calculation of l z . The area under the concentration-time curve (AUC) was no pattern of abnormal laboratory values, vital signs (including ECG) or neurological assessments observed was calculated by linear trapezoidal summation and extrapolation to infinity in case of exogenous levodopa administration during the study to suggest a treatment effect. Some subjects showed low haematocrit values towards the end of the study [17] . The AUC ratios for 3-OMD/levodopa and DOPAC/ levodopa following the different benserazide doses were also which could be explained by the amount of blood withdrawn. calculated because these quotients may have more clinical relevance than concentrations of an analyte as such [18, 19] .
Pharmacokinetics
Statistics In addition to descriptive statistics (mean, s.d., 95% confidence intervals of the differences in mean values
The plasma concentration-time profiles of endogenous levodopa, 3-OMD and DOPAC on study days −1, 14, 28 versus the control group), statistical analysis was performed to discriminate the mean pharmacokinetic parameters of the and 42 are presented in Figure 1 . The derived pharmacokinetic parameters (C max and AUC) are given in Table 1 Table 2 . For C max of levodopa, doses Tolerability of 12.5 mg and above differed from the control value whereas t max was not dose-dependent. AUC and t 1/2,z of All 16 subjects completed the study according to the protocol. There was no clear pattern of adverse events levodopa differed significantly (P<0.05) from pretreatment values from 5 mg and 50 mg, respectively, onwards. With which could be attributed to benserazide and/or levodopa. In particular, there were no signs of increased dopaminergic respect to DOPAC, only C max and AUC showed significant (P<0.05) differences compared with pretreatment conactivity such as nausea, vomiting, and orthostatic complaints on days of levodopa intake. Four adverse events were ditions (doses of 5 mg and above). 3-OMD showed the same pattern as DOPAC with regard to C max and AUC reported to be of severe intensity. Two subjects had a severe and, in addition, t 1/2,z at 200 mg differed significantly plasma levels of levodopa and 3-OMD [16] . This provided an indirect marker of decarboxylase activity which is (P<0.05) from control. With respect to t max , values for both DOPAC and 3-OMD were not dependent on the therapeutically most relevant because levodopa in clinical practice is nearly always combined with benserazide or benserazide dose regimen. Figure 4 depicts the AUC ratios of 3-OMD vs levodopa carbidopa.
Benserazide elicited a dose-dependent increase in and DOPAC vs levodopa as a function of the benserazide dose. Both ratios demonstrated a statistically significant endogenous levodopa levels. There were no clear indications that a maximum response to benserazide had been attained dose-dependency.
at a dose of 200 mg three times daily. Levodopa levels of subjects treated with 50-200 mg three times daily benserazDiscussion ide were at their lowest (P<0.05) 6 h after the morning dose of benserazide. This suggests that at least at these doses The data reported in this paper constitute a detailed investigation of the pharmacodynamics of benserazide.
benserazide does not lead to constant decarboxylase inhibition. Consequently, it is unlikely that benserazide's Although known for more than two decades as a potent inhibitor of peripheral decarboxylase [20] , its clinical mechanism of action is completely irreversible [22] . This is in accordance with findings obtained by Da Prada et al. [23] pharmacology has been sparsely investigated. The main reasons for this lack of data are the complex analysis of who showed that the effect of a single dose of benserazide (1.5 mg kg −1 ) on endogenous levodopa levels decreased benserazide and/or its active metabolite(s) and the absence of a suitable direct marker of decarboxylase activity [3] . By after 3 h following administration. Under physiological conditions decarboxylation activity was found to be rather contrast, COMT and MAO-B activity, which are other pivotal enzymes in the metabolism of levodopa, can be constant at different times of the day [24] . The slight fluctuations in the extent of decarboxylase inhibition over relatively easily measured in erythrocytes and thrombocytes, respectively [13, 21] . The availability of a very sensitive the day due to benserazide were not reflected in the 3-OMD levels in accord with its long plasma half-life [25, assay method enabled the determination of endogenous 26]. The increase in 3-OMD concentration as a function of on 3-OMD levels was much more pronounced: 200 mg benserazide three times daily increased the AUC of 3-OMD benserazide dose indicated that with increasing decarboxylase inhibition the metabolism of levodopa is shifted towards the about 14-fold whereas the AUC of levodopa increased only five-fold. Relatively high doses of carbidopa have also been 3-OMD pathway. Levels of DOPAC, the MAO-B derived metabolite of levodopa, hardly decreased with ascending shown to significantly increase the AUC of 3-OMD without a concomitant effect on levodopa AUC [30] . These doses of benserazide. This suggests that endogenously present DOPAC mainly originates from dopamine within the brain. divergent effects of decarboxylase inhibitors on levodopa and 3-OMD are difficult to explain because 3-OMD is a Benserazide dose-dependently increased the AUC of levodopa when the latter was administered as a 250 mg poor substrate for decarboxylase [14] . It should, however, be realised that alternative metabolic pathways of levodopa dose. The difference in response with respect to levodopa AUC between benserazide 100 and 200 mg three times become more prominent when decarboxylase is inhibited. Although benserazide has been reported to be a COMT daily was negligible. Relatively high doses are necessary to induce complete inhibition of decarboxylase as has also been substrate [31] , this study provided no evidence for a COMT inhibitory effect [32] . The role of 3-OMD in the complidemonstrated for carbidopa [27] . Addition of benserazide or carbidopa to levodopa formulations in the ratio 154 has cations inherent to long-term levodopa therapy has not been completely elucidated [33] . 3-OMD is devoid of generally been shown to increase the latter's systemic exposure by a factor of about two [28] . The more antiparkinsonian activity but may compete with levodopa for transport across the blood-brain barrier [34, 35] . pronounced effects in this study, also at daily benserazide doses of 75-150 mg, can probably be explained by the However, a recently conducted positron emission tomography study questioned competition between levodopa and subchronic treatment with benserazide resulting in a larger extent of decarboxylase inhibition. As reported by other 3-OMD at clinically relevant concentrations [36] . A high ratio of 3-OMD/levodopa levels has been suggested to investigators, t max and C max after oral levodopa administration showed a marked intersubject variability [14, 29] . The effect reflect a poor response to levodopa therapy [19, 37] . With ascending benserazide dose, the 3-OMD/levodopa AUC containing abundant decarboxylase activity [38, 39] . Levodopa and DOPAC had very similar half-lives which ratio increased (Figure 4 ), thus providing a rationale for triple therapy with levodopa, and inhibitors of both could indicate that decarboxylation rather than deamination is the rate-limiting step in the formation of DOPAC. The decarboxylase and COMT [8] .
Patients with Parkinson's disease are treated with a wide finding that peripheral decarboxylase inhibitors do not clearly prolong the t 1/2 of levodopa has been reported range of doses of levodopa/decarboxylase inhibitor. A dosing regimen of levodopa/benserazide 100/25 mg four to five previously [28, 40] . Robertson et al. showed that carbidopa increased t 1/2 of oral levodopa only in the elderly [11] . This times a day can be considered as average in moderately ill patients without major response fluctuations. Under these is in contrast to the effect of the potent COMT inhibitor tolcapone which increased the t 1/2 of levodopa by up to conditions decarboxylase is obviously only partially inhibited. Despite peripheral dopamine formation, the tolerability of 90% [10] . The results of this study indicate that lowering of the all treatments in the present study was very good, although one should realise that only single doses of levodopa were levodopa/benserazide combination dose, in the context of attempts to limit the adverse effects of long-term levodopa given on some separate days. The effect of a low dosing regimen of benserazide (5 mg three times daily) on DOPAC therapy, could result in a reduction of the dose-normalised levodopa exposure. The mechanism underlying this levels was striking. Its AUC was halved and its C max was reduced to one third of that in the absence of benserazide.
phenomenon is a less complete inhibition of peripheral decarboxylase. No signs, however, were observed which Higher doses of benserazide further reduced levels of DOPAC. This indicates that after administration of levodopa would suggest a parallel poorer tolerability in terms of increased dopaminergic side-effects. Similar or even more the major portion of DOPAC is formed peripherally. The t max of levodopa, 3-OMD and DOPAC were very similar marked dose-dependency in the inhibition of decarboxylase is anticipated for levodopa preparations containing carbidopa under the different benserazide regimens and t 1/2 only increased slightly at doses of 100-200 mg (Table 2 ). These since this inhibitor is less potent than benserazide [23, 27] . The clinical development of COMT inhibitors should take results, together with the C max and AUC data, suggest that decarboxylase present in the gastrointestinal tract plays a these possible consequences of lowering the benserazide dose into consideration by the conduct of pharmacokinetic/ crucial role in the metabolism of levodopa to dopamine. This is in accordance with the gastric and intestinal mucosa pharmacodynamic interaction studies with the COMT 
